EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation

Da Eun Lee iD, Geunho Lim iD, Minoh Ko iD, Mari Kim iD, Ji Sun Chun iD, Borim Lee iD, Miso Kim iD, Kwangsoo Kim iD, Byung Kwan Choi iD, Jeongmin Seo iD, Jin Hyoung Kang iD, Taehoon Ko iD und 2 weitere

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70424 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Da Eun Lee und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Glucocorticoids, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non–small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias. We conducted a multicenter target trial emulation to assess the association of glucocorticoid timing and dose with survival outcomes while addressing these biases. Patients with advanced NSCLC who initiated ICI therapy between 2015 and 2021 at four Korean tertiary hospitals were included. The primary endpoint was 2‐year overall survival (OS), with disease progression as a secondary endpoint. To minimize biases, outcomes were compared between concomitant glucocorticoid users and non‐users using time‐dependent propensity score matching. Among 1,815 eligible patients, 1,128 were matched. Hazard ratios (HRs) from the four institutions were pooled using a random‐effects meta‐analysis. Concomitant glucocorticoid use was associated with an increased risk of mortality (pooled aHR 1.36; 95% CI, 1.06–1.75). Early exposure within 90 days of ICI initiation was associated with poorer OS (aHR 1.49; 95% CI, 1.18–1.87), whereas later initiation showed no association. Dose‐stratified analyses showed that high‐dose exposure (> 1 mg/kg/day) was associated with reduced survival (aHR 1.61; 95% CI, 1.31–1.99), whereas low‐dose exposure was not associated with adverse outcomes. After accounting for confounding by indication and time‐related biases, concomitant systemic glucocorticoid use during ICI therapy was associated with less favorable survival outcomes. This association was more pronounced with early and high‐dose exposure, underscoring the clinical importance of glucocorticoid timing and dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungGlucocorticoidsImmune Checkpoint InhibitorsLung NeoplasmsAgedFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugRepublic of KoreaTime Factors

Substanzen

GlucocorticoidsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
  • College of Pharmacy, Daegu Catholic University, Gyeongsan-si, Republic of Korea.
  • Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Medicine, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Center for Data Science, Healthcare AI Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.

ORCID-Profile: Da Eun Lee, Geunho Lim, Minoh Ko, Mari Kim, Ji Sun Chun, Borim Lee, Miso Kim, Kwangsoo Kim, Byung Kwan Choi, Jeongmin Seo, Jin Hyoung Kang, Taehoon Ko, In-Wha Kim, Jung Mi Oh

Zitieren

APA

Lee, D. E., Lim, G., Ko, M., Kim, M., Chun, J. S., Lee, B., Kim, M., Kim, K., Choi, B. K., Seo, J., Kang, J. H., Ko, T., Kim, I. W., & Oh, J. M. (2026). Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70424

Vancouver

Lee DE, Lim G, Ko M, Kim M, Chun JS, Lee B, et al. Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70424

BibTeX
@article{Lee2026,
  author = {Lee, Da Eun and Lim, Geunho and Ko, Minoh and Kim, Mari and Chun, Ji Sun and Lee, Borim and Kim, Miso and Kim, Kwangsoo and Choi, Byung Kwan and Seo, Jeongmin and Kang, Jin Hyoung and Ko, Taehoon and Kim, In-Wha and Oh, Jung Mi},
  title = {Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70424}
}
Kostenlos starten →